SEC Info - Annovis Bio, Inc. - IPO: ‘S-1’ on 7/2/19

SEC Info℠

Home

Help

Please Sign In

Annovis Bio, Inc. – IPO: ‘S-1’ on 7/2/19 – ‘EX-23.1’

On: Tuesday, 7/2/19, at 9:15pm ET · As of: 7/3/19 · Accession #: 1047469-19-3982 · File #: 333-232529

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 7/03/19  Annovis Bio, Inc.                 S-1                   10:4.8M                                   Merrill Corp/New/FA

Initial Public Offering (IPO): Registration Statement (General Form) — Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.28M 
 2: EX-3.1      Articles of Incorporation/Organization or By-Laws   HTML    216K 
 3: EX-3.3      Articles of Incorporation/Organization or By-Laws   HTML     90K 
 4: EX-10.1     Material Contract                                   HTML     49K 
 5: EX-10.2     Material Contract                                   HTML     77K 
 6: EX-10.3     Material Contract                                   HTML    139K 
 7: EX-10.4     Material Contract                                   HTML    105K 
 8: EX-10.6     Material Contract                                   HTML     20K 
 9: EX-10.7     Material Contract                                   HTML     66K 
10: EX-23.1     Consent of Experts or Counsel                       HTML      7K

‘EX-23.1’ — Consent of Experts or Counsel

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Preliminary Prospectus constituting a part of this Registration Statement on Form S-1 of Annovis Bio, Inc. of our report dated May 15, 2019, except for the effects on the financial statements of the restatement described in Note 12, as to which the date is July 2, 2019, relating to the balance sheets of Annovis Bio, Inc. as of December 31, 2018 and 2017, and the related statements of operations, changes of redeemable convertible preferred stock and stockholders’ equity (deficit) and cash flows for each of the two years in the period then ended.

We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ WithumSmith+Brown, PC

East Brunswick, New Jersey
July 2, 2019

Dates Referenced Herein

This ‘S-1’ Filing	Date	Other Filings

Filed as of:	7/3/19	None on these Dates
Filed on:	7/2/19
	5/15/19
	12/31/18
	12/31/17
		List all Filings

8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/29/24  Annovis Bio, Inc.                 10-K       12/31/23   68:6.9M                                   Toppan Merrill Bridge/FA
 3/31/23  Annovis Bio, Inc.                 10-K       12/31/22   70:9.7M                                   Toppan Merrill/FA
 3/02/22  Annovis Bio, Inc.                 10-K       12/31/21   66:5.9M                                   Toppan Merrill Bridge/FA
11/17/21  Annovis Bio, Inc.                 8-A12B                 1:17K                                    Toppan Merrill/FA
 3/03/21  Annovis Bio, Inc.                 10-K       12/31/20   63:5.1M                                   Toppan Merrill Bridge/FA
 9/10/19  SEC                               UPLOAD¶     2/26/20    2:48K  Annovis Bio, Inc.
 8/20/19  SEC                               UPLOAD¶     2/26/20    2:56K  Annovis Bio, Inc.
 7/15/19  SEC                               UPLOAD¶     2/26/20    2:57K  Annovis Bio, Inc.

↑Top

Filing Submission 0001047469-19-003982 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)